Microneedles, particularly drug-loaded microneedles, exhibit fundamental differences in business model compared to traditional minimally invasive surgical devices. The value of traditional surgical consumables (e.g., puncture needles, shavers) lies in their mechanical function and reliability, with business models typically centered on "device + dedicated consumables" or standalone consumable sales. In contrast, the core value of microneedles-especially those integrated with drugs/bioactive ingredients-resides in their delivery function, positioning them more akin to "drug delivery platforms" or "active ingredient release systems." This fundamental shift in nature profoundly reshapes and challenges the commercial logic, customer relationships, and revenue models of minimally invasive surgical device manufacturers.

The Primary Challenge: Shifting Value Distribution and Customer Dynamics

In the traditional model, manufacturers' direct customers are medical device brands, with a relatively clear value chain. However, in the microneedle space-particularly for pharmaceutical applications-the ultimate value is determined by drug efficacy. Consequently, manufacturers may need to establish deep partnerships directly with pharmaceutical companies. These collaborations extend beyond simple build-to-print manufacturing, encompassing end-to-end co-development from drug formulation compatibility and microneedle design to preclinical research support and scaled production. Manufacturers' intellectual property (IP) is no longer limited to manufacturing processes; it may expand to delivery system designs tailored to specific drugs. This demands robust application development teams and regulatory registration support capabilities, transforming manufacturers' roles from contractors to co-developers.

Diversified Revenue Models

Accordingly, revenue models have diversified:

High-End Custom Development & Manufacturing: Delivering end-to-end solutions from design to production for novel pharmaceutical molecules, with substantial R&D and manufacturing fees charged per project. This model features the highest technical barriers and profit margins.

Patent Licensing & Royalties: Manufacturers holding core patents for microneedle structures or materials can license these to pharmaceutical or large device companies, earning royalties based on product sales. This converts technological advantages into sustained, predictable cash flow.

Scaled Consumable Supply: In medical aesthetics or established transdermal drug delivery sectors, microneedles are sold as core consumables in treatment heads or patches. Most similar to the traditional model, this segment faces fierce competition, with cost control as the critical success factor.

Strategic Imperatives for Manufacturers

Strategic positioning is pivotal for manufacturers. Will you position your company as a R&D and production hub for "secret weapons" of pharmaceutical giants, focusing on high-threshold, high-margin custom projects? Or as a scaled, low-cost consumable supplier for the medical aesthetics and consumer health sectors, prioritizing market share? Alternatively, pursue a dual-path strategy-though this requires establishing distinct business units and capability frameworks.

Regardless of the chosen path, manufacturers must build capabilities beyond manufacturing: foundational knowledge of pharmaceutical/cosmetic formulations, preclinical research management expertise, regulatory agency liaison capabilities, and comprehensive IP strategy planning. Microneedle commercialization tests not only factory production capacity but also an enterprise's system integration and ecosystem-building capabilities as a "platform-type supplier".